Collegium Pharmaceutical (COLL) Q2 2026 Earnings Call Transcript

Collegium Pharmaceutical (COLL) reported Q2 2026 results on an earnings call. Total net product revenue was $199.9M (+6% YoY). Jornay PM revenue rose to $46.1M (+41%) with 30,000+ prescribers. Azstarys revenue was $12.9M post-May acquisition. 2026 guidance: product revenue $825M-$855M; adjusted EBITDA $445M-$470M; adjusted EPS $1.92. Risks cited include authorized-generic pricing impacts.

Original reporting
Published Aug 13, 2026, 1:45 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 13, 2026, 2:14 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Collegium Pharmaceutical (COLL) Q2 2026 Earnings Call Transcript — source image
Decision brief

The 30-second read

$COLLNeutralMed
01

Why it matters

Traders should focus on the updated FY2026 guidance ranges and management’s stated drivers: lower Nucynta franchise revenue from authorized generic net pricing, partially offset by higher Azstarys revenue outlook and continued Jornay PM share gains.

02

Market read

The article contains a full set of quarterly metrics plus explicit FY2026 guidance revisions, making it actionable for re-pricing expectations around ADHD growth versus pain pricing risk.

03

What to watch

Authorized generic settlement terms and the potential Belbuca generic launch timing (Jan 2027) could create a forward-looking overhang not fully captured by the current quarter’s numbers.

Relevance 8/10Novelty 7/10Timing: post-earnings call, guidance update for FY2026

Background

This is Collegium Pharmaceutical’s Q2 2026 earnings call transcript, covering ADHD franchise performance, the May Azstarys acquisition integration, and pain portfolio pricing headwinds.

Company-level read

Ticker impact

$COLLNeutralMedium confidence
Context

Collegium reported Q2 results and updated 2026 guidance, including Azstarys revenue range and lower Nucynta franchise outlook tied to authorized generic pricing.

Expected impact

Likely choppy trading around guidance interpretation, with upside bias if investors focus on Jornay PM share gains and Azstarys ramp, offset by concerns over Nucynta pricing pressure.

Evidence & confidence

The article provides multiple hard guidance datapoints (revenue, adjusted EBITDA, EPS) plus explicit management rationale for the Nucynta franchise reset from authorized generic dynamics, which are direct drivers for earnings expectations.

Market effects

Highlights ongoing competitive pricing pressure in branded opioid and authorized-generic frameworks, while ADHD CNS brands can still gain share via prescriber expansion.

Limited; company-specific US commercial dynamics dominate.

Limited; primarily US formulary and prescriber adoption metrics.

Counterpoint

The Azstarys guidance increase may be partially offset by continued margin pressure from pain franchise authorized generic dynamics, so the net earnings quality could be weaker than revenue growth suggests.

Key entities

  • Collegium Pharmaceutical, Inc.

    Subject of the earnings call, reporting Q2 results and updating 2026 guidance across ADHD and pain products.

  • Azstarys

    ADHD medicine acquired in May, with guidance increased to $65M-$75M for 2026.

  • Nucynta franchise

    Pain portfolio segment facing lower net pricing for authorized generics, driving guidance changes.

  • Belbuca

    Pain medicine where management referenced settlement-related generic launch risk in Jan 2027.

Related articles

$COLLMedAI 8/10

Collegium Pharmaceutical Earnings Call Highlights ADHD Growth

Collegium Pharmaceutical (COLL) reported Q3 record revenue of $216.3M, up 3% YoY, driven by ADHD products (36% of total revenue). Jornay PM grew 24% YoY to $52M-$59.5M, while Azstarys saw 2% prescription growth. Pain portfolio revenue declined 9% YoY. Adjusted EBITDA fell 9% to $121.6M. The company reaffirmed 2026 guidance, expecting flat adjusted EBITDA.

$COLLMed

Jefferies cuts Collegium Pharmaceutical stock price target on pain business concerns

Jefferies reduced its price target for Collegium Pharmaceutical (COLL) to $35 from $51, citing concerns about its pain business. The stock is down 45.66% year-to-date. The company reported Q3 2026 earnings, beating EPS estimates but meeting revenue expectations. Management plans to continue share buybacks and deleverage. Jefferies expects modest EBITDA growth by 2027, with ADHD business growth offsetting pain segment declines.

$COLLMed

Collegium (COLL) Q3 2026 Earnings Call Transcript

Collegium (COLL) reported Q3 2026 net revenue of $216.3M, up 3% YoY. Jornay PM prescriptions grew 16% YoY, generating $59.5M in revenue. Azstarys revenue was $26.5M, with prescriptions up nearly 2% YoY. The company reaffirmed full-year guidance and announced a $50M share repurchase program.

$COLLMed

Collegium Pharmaceutical Q3 Earnings Call Highlights

Collegium Pharmaceutical reported Q3 revenue of $138M from its pain portfolio, with BELBUCA sales at $57.7M, XTAMPZA ER at $45.8M, and NUCYNTA at $30.8M. The company expects AZSTARYS prescription growth to accelerate in 2027 and reaffirmed its 2026 revenue forecast of $825M-$855M. It plans a $50M share repurchase and has $100M remaining under its authorization.